Nicotine patch claims are one quarter of 1997 OTC/supplement NAD reviews.
This article was originally published in The Tan Sheet
Executive Summary
NICOTINE REPLACEMENT PATCHES GENERATE A QUARTER OF NAD REVIEWS involving OTC drugs, dietary supplements and infant formulas in 1997. The National Advertising Division of the Council of Better Business Bureaus completed 16 OTC, supplement and formula cases during the year, of which four were smoking cessation patch products -- two for McNeil Consumer Product's Nicotrol and two for SmithKline Beecham's NicoDerm CQ. The number of OTC/supplement/formula cases is down 30% from 1996, when NAD completed 23 reviews, reflecting lower 1997 NAD totals in general due to limited resources and a smaller staff, as well as NAD's concentration on new product categories such as the telecommunications industry
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.